SCHEMBL4040144

SCHEMBL4040144

Cc1nc(NC2CCN(Cc3ccccc3)CC2)cc(-n2nc(Nc3ccccc3)nc2N)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.48
ACHE P22303 8/20 0.46
PDE5A O76074 2/20 0.43
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
BACE1 P56817 1/20 0.42
NSD2 O96028 1/20 0.41
BCHE P06276 1/20 0.41
ROCK2 O75116 1/20 0.41
CCR2 P41597 1/20 0.41
ROCK1 Q13464 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KIT P10721 1/20 0.41
FLT3 P36888 1/20 0.41
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048046 0.88 ALDH1A1 (0.49) HRH3ACHEALDH1A1L3MBTL1BACE1
SCHEMBL12779910 0.86 HRH3 (0.51) HRH3ACHEPDE5AALDH1A1L3MBTL1
SCHEMBL4044430 0.86 MEN1 (0.44) SMN1; SMN2KITFLT3
SCHEMBL4037660 0.84 PAK4 (0.41) HRH3ROCK1KITFLT3
SCHEMBL4041179 0.81 CXCR4 (0.45) HRH3ACHEPDE5AALDH1A1L3MBTL1
SCHEMBL12780385 0.81 CXCR4 (0.45) HRH3ACHEPDE5AALDH1A1L3MBTL1
SCHEMBL4047090 0.81 EHMT2 (0.48) ACHEPDE5ANSD2KITFLT3
SCHEMBL4040588 0.81 EHMT2 (0.47) ACHEPDE5ANSD2KITFLT3
SCHEMBL2086901 0.79 FLT3 (0.47) KITFLT3
SCHEMBL12779942 0.76 KIT (0.59) HRH3ACHEALDH1A1L3MBTL1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 HRH3 1008/4885ACHE 2344/4885PDE5A 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.